Beta

Scilex holding companySCLX.US Overview

US StockHealthcare
(No presentation for SCLX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

SCLX AI Insights

SCLX Overall Performance

SCLX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SCLX Recent Performance

0.29%

Scilex holding company

-1.10%

Avg of Sector

-0.49%

S&P500

SCLX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check SCLX's Trend

SCLX Key Information

SCLX Valuation Metrics

SCLX Profile

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Price of SCLX

SCLX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-42.25
PE Ratio (TTM)
-
Forward PE
2.66
PS Ratio (TTM)
1.56
PB Ratio
28.85
Price-to-FCF
15.86
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.97%
Net Margin
-1185.78%
Revenue Growth (YoY)
-46.54%
Profit Growth (YoY)
-50.74%
3-Year Revenue Growth
-26.19%
3-Year Profit Growth
-33.49%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-42.25
PE Ratio (TTM)
-
Forward PE
2.66
PS Ratio (TTM)
1.56
PB Ratio
28.85
Price-to-FCF
15.86
Gross Margin
64.97%
Net Margin
-1185.78%
Revenue Growth (YoY)
-46.54%
Profit Growth (YoY)
-50.74%
3-Year Revenue Growth
-26.19%
3-Year Profit Growth
-33.49%
  • When is SCLX's latest earnings report released?

    The most recent financial report for Scilex holding company (SCLX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SCLX's short-term business performance and financial health. For the latest updates on SCLX's earnings releases, visit this page regularly.

  • What is the operating profit of SCLX?

    According to the latest financial report, Scilex holding company (SCLX) reported an Operating Profit of -111.09M with an Operating Margin of -2,317.76% this period, representing a decline of 291.47% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SCLX's revenue growth?

    In the latest financial report, Scilex holding company (SCLX) announced revenue of 4.79M, with a Year-Over-Year growth rate of -67.83%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does SCLX have?

    As of the end of the reporting period, Scilex holding company (SCLX) had total debt of 132.54M, with a debt ratio of 0.36. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SCLX have?

    At the end of the period, Scilex holding company (SCLX) held Total Cash and Cash Equivalents of 4.96M, accounting for 0.01 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SCLX go with three margins increasing?

    In the latest report, Scilex holding company (SCLX) did not achieve the “three margins increasing” benchmark, with a gross margin of 45.5%%, operating margin of -2,317.76%%, and net margin of -690.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SCLX's profit trajectory and future growth potential.

  • What is the FCF of SCLX?

    Scilex holding company (SCLX)'s Free Cash Flow (FCF) for the period is -17.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 794.71% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SCLX?

    The latest valuation data shows Scilex holding company (SCLX) has a Price-To-Earnings (PE) ratio of -0.14 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

SCLX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1